1-3 of 3
Eric Humphriss
Close
Sort by
Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, Digumarti Raghunadharao, MD, Purvish Parikh, MD, Meir Wetzler, MD, Jeffrey H. Lipton, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Hagop M. Kantarjian, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Franck Emmanuel Nicolini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 861.
https://doi.org/10.1182/blood.V114.22.861.861
Published: 2009
Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, H. Jean Khoury, MD, FACP, Franck Emmanuel Nicolini, MD, PhD, Selim Corm, Jeffrey H. Lipton, MD,PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 644.
https://doi.org/10.1182/blood.V114.22.644.644
Published: 2009
Journal Articles

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

Jorge Cortes, MD, H. Jean Khoury, MD, Sélim Corm, MD, Franck E Nicolini, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, MD, Eric Humphriss, Hagop Kantarjian
Journal: Blood
Blood (2008) 112 (11): 3239.
https://doi.org/10.1182/blood.V112.11.3239.3239
Published: 2008